No Protective Effect of Calcitriol on β-Cell Function in Recent-Onset Type 1 Diabetes The IMDIAB XIII trial
No Protective Effect of Calcitriol on β-Cell Function in Recent-Onset Type 1 Diabetes The IMDIAB XIII trial
复制标题
DOI：
10.2337/dc10-0814
复制
发表时间：
2010-09-01
期刊：
影响因子：
16.2
通讯作者：
Pozzilli, Paolo
中科院分区：
文献类型：
--
作者：
Bizzarri, Carla;Pitocco, Dario;Pozzilli, Paolo
目的：我们研究补充活性形式的维生素D是否（骨化三醇）在新近发作的I型糖尿病中可以保护通过C肽评估的β细胞功能，并改善通过A1 C和胰岛素需求评估的血糖控制。（11-35岁，中位年龄18岁），近期发病的1型糖尿病和高基础C-肽>0.25 nmol/l，在一项双盲试验中随机分配至0.25 μ g/天骨化三醇或安慰剂组，并随访-结果-在6个月、12个月和24个月的随访中，骨化三醇组的A1 C和胰岛素需求与安慰剂组没有差异。C-肽显著下降（P < 0.001），但两组相似，在每个时间点无显著差异。结论-在所用剂量下，骨化三醇对近期发病的I型糖尿病和诊断时C-肽水平高的受试者（包括儿童）的β细胞功能保护无效。
OBJECTIVE - We investigated whether supplementation of the active form of vitamin D (calcitriol) in recent-onset type I diabetes can protect beta-cell function evaluated by C-peptide and improve glycemic control assessed by A1C and insulin requirement.RESEARCH DESIGN AND METHODS - Thirty-four subjects (aged 11-35 years, median 18 years) with recent-onset type 1 diabetes and high basal C-peptide >0.25 nmol/l were randomized in a double-blind trial to 0.25 mu g/day calcitriol or placebo and followed-up for 2 years.RESULTS - At 6, 12, and 24 months follow-up, A1C and insulin requirement in the calcitriol group did not differ from the placebo group. C-peptide dropped significantly (P < 0.001) but similarly in both groups, with no significant differences at each time point.CONCLUSIONS - At the doses used, calcitriol is ineffective in protecting beta-cell function in subjects (including children) with recent-onset type I diabetes and high C-peptide at diagnosis.